Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
INTERVENTIONAL
2000-07-31
2006-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vincristine
Steroids pre-treatment
Vincristin, Daunorubicine, Asparaginase, Methotrexate
Induction therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Negative myeloperoxidase stain
* Phenotype T (ALL-T) and B(ALL-B)
Exclusion Criteria
* LVEF \<50%
* Presence of documented infections not responding to antibiotic and/or antifungal therapy
* Presence of concomitant malignant diseases
* Absence of any psychological condition that does not allow to intake high doses of cortisone
* Patients who have received any antineoplastic chemiotherapy for more than 5 days
* Patients who have received any steroids for more than 10 days
14 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gruppo Italiano Malattie EMatologiche dell'Adulto
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Franco MANDELLI, Pr
Role: PRINCIPAL_INVESTIGATOR
Università degli Studi di Roma "La Sapienza"
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Az. Ospedaliera S. G. Moscati
Avellino, , Italy
Ist.Ematologia e Oncologia Medica L.e A. Seragnoli
Bologna, , Italy
Ospedale Reg. A di Summa
Brindisi, , Italy
Istituto di Ematologia- Ospedale San Carlo
Potenza, , Italy
Policlinico G.B. Rossi
Verona, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Piciocchi A, Messina M, Elia L, Vitale A, Soddu S, Testi AM, Chiaretti S, Mancini M, Albano F, Spadano A, Krampera M, Bonifacio M, Cairoli R, Vetro C, Colella F, Ferrara F, Cimino G, Bassan R, Fazi P, Vignetti M. Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996. Am J Hematol. 2021 Sep 1;96(9):E334-E338. doi: 10.1002/ajh.26253. Epub 2021 Jun 9. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LAL2000
Identifier Type: -
Identifier Source: org_study_id